About Lundbeck

Lundbeck is a global pharmaceutical company conducting research into, developing, manufacturing, marketing, selling and distributing pharmaceuticals for the treatment of disorders in the central nervous system (CNS), including depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, Huntington's disease, epilepsy and insomnia.

More information about Lundbeck

Brain disorders
According to the World Health Organization, WHO, more than 700 million cases of brain disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives.

As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionised the treatment options, but there remains a large unmet need for new and innovative therapeutics.

More information about diseases

Research and pipeline
Lundbeck is one of Denmark’s most research-intensive enterprises. We employ a total of 1,200 highly-trained specialists in our research and development units. Each year, Lundbeck ploughs back more than 20% of its revenue into research and development of new pharmaceuticals to improve treatment options for the millions of people around the world suffering from neurological disorders.

More information about developing drugs

Products
Lundbeck markets a number of different pharmaceuticals for the treatment of disorders of the central nervous system (CNS). The most recently launched compounds include: Cipralex/Lexapro (depression), Ebixa (Alzheimer’s disease), Azilect (Parkinson’s disease), Xenazine (chorea associated with Huntington's disease), Serdolect (schizophrenia), Sabril (epilepsy) and Circadin (sleep disorders). Click on the products for more information.

Key figures
Lundbeck employs 5,900 people worldwide, 2,100 of whom are based in Denmark. We have employees in 56 countries, and our products are registered in more than 100 countries. We have production facilities in Italy and Denmark and research centres in Denmark and the USA. Lundbeck generated revenue of approximately DKK 13,7 billion in 2009.

More key figures
Financial reports

Management
Lundbeck’s overall management consists of our Executive Management (six members) headed by Ulf Wiinberg, President and CEO.

More information about management

Market data
In 2009, 54% of our revenue derived from Europe, 27% from the USA and 19% from the International Markets region.

More information about markets

History
Lundbeck was founded by Hans Lundbeck as a trading company in 1915. Since then the company has evolved and grown dramatically. Today we are among the biggest Danish companies.

More information about our history
 

Ownership
In 1999, Lundbeck’s shares were listed on the Copenhagen Stock Exchange. The Lundbeck Foundation, which distributes more than DKK 300 million in grants for various types of research each year, owns about 70% of the shares in Lundbeck, while the remaining 30% are traded on the stock exchange.

Current market price and market capitalisation